SMS Pharmaceuticals grows FY26 revenue to ₹886.87 cr
The company’s annual results reflect steady growth alongside a final dividend of ₹0.40 per share.
— 2 earlier stories on SMS Pharmaceuticals Ltd. →What's new with SMS Pharmaceuticals Ltd.
- Standalone revenue rose 13.3% YoY to ₹886.87 cr.
- Net profit climbed 28.1% to ₹87.61 cr.
- The board proposed a final dividend of ₹0.40 per share.
Why this matters for SMS Pharmaceuticals Ltd.
The company delivered growth in line with expectations. There are no surprises here, just standard operational performance confirmed by an unmodified audit opinion.
What we're watching
- Future capacity utilization updates.
- Updates on the office shift logistics.
- Any material deviation in quarterly margins.
The full read
SMS Pharmaceuticals posted its FY26 audited results, confirming a year of consistent, anticipated growth. Standalone revenue hit ₹886.87 crore, a 13.3% increase over the previous year, while net profit rose more sharply by 28.1% to reach ₹87.61 crore. The board declared a final dividend of ₹0.40 per share, maintaining a conservative payout profile. With an unmodified audit opinion and standard administrative updates regarding office shifts and auditor appointments, the filing adds no new tactical information to the company's existing trajectory. It is a clean, routine disclosure of financial performance that mirrors the market's expected baseline.